Valneva Se · EURONEXT:VLA
Valneva — H1 2025 Earnings Presentation
25 slides from Valneva's earnings presentation, Aug 12, 2025
Slide 1: Valneva Reports First Half 2025 Financial Results and Provides Corporate Updates
Valneva Reports First Half 2025 Financial Results and Provides Corporate Updates August 12, 2025
Slide 2: Disclaimer
Disclaimer This presentation does not contain or constitute an offer of, or the solicitation of an Certain information and statements included in this presentation are not historical offer to buy or subscribe for, Valneva SE shares to any person in the USA or in any facts but are forward-looking sta
Slide 3: Agenda
Agenda Introduction Business Update Financial Report H1 2025 Financial Outlook Growth Drivers Q&A Valneva – H1 2025 Analyst Presentation 3
Slide 4: First Half 2025 Key Highlights
First Half 2025 Key Highlights Total Revenues Cash Position €97.6m €161.3m 38% year-over-year growth Includes €20.1m net proceeds from strategic ATM transactions1 H1 2025 Further Pipeline and Significant Reduction in Regulatory progress Operating Cash Burn4 Targeting 50% reduction Lyme , IXCHIQ®, Sh
Slide 5: First Half 2025 Highlights
First Half 2025 Highlights Fulfilling Unmet Medical Needs ▪ Finalized new $32.8 million IXIARO® U.S. Department of Defense contract ▪ Responded to French government’s call for IXCHIQ ® to combat chikungunya outbreaks in La Réunion and Mayotte ▪ Responded to cholera outbreak in Mayotte by supplying d
Slide 6: Agenda
Agenda Introduction Business Update Financial Report H1 2025 Financial Outlook Growth Drivers Q&A Valneva – H1 2025 Analyst Presentation 6
Slide 7: World’s leading Lyme Disease Vaccine Candidate
World’s leading Lyme Disease Vaccine Candidate VLA15
Slide 8: Lyme Disease Represents A Major Medical Need And Market Opportunity
Lyme Disease Represents A Major Medical Need And Market Opportunity No vaccine is currently available to prevent Lyme disease in humans Annual Burden of Disease Commercial opportunity for Valneva U.S.1 Europe2 U.S. Europe ~476K cases >132K cases 87 million 223 million Severe Manifestations3 Populati
Slide 9: Phase 3: Vaccination Completed; First Data Readout Expected at the End of 2025
Phase 3: Vaccination Completed; First Data Readout Expected at the End of 2025 Pfizer aims to submit regulatory applications in U.S. and Europe in 20261 ▪ Population: ~9,400 evaluable participants ≥5 years of age at high risk of Lyme disease (LD) (by residence and occupational/recreational activitie
Slide 10: A Highly Differentiated single-shot Chikungunya Vaccine
A Highly Differentiated single-shot Chikungunya Vaccine IXCHIQ® / VLA1553 IXCHIQ® is approved by the European Medicines Agency (EMA) in individuals 12 years of age and older. It is approved by the U.S. Food & Drug Administration (FDA), the UK’s Medicines and Healthcare products Regulatory Agency (MH
Slide 11: Recent Regulatory Updates for IXCHIQ®
Recent Regulatory Updates for IXCHIQ® FDA and EMA have now lifted the temporary restrictions against use in elderly Reports of serious adverse events (SAEs) in frail elderly individuals ▪ Primarily among elderly individuals with multiple underlying health conditions, following a mass vaccination cam
Slide 12: IXCHIQ®: Focused on Expanding Access, Label Extension, Product Profile
IXCHIQ®: Focused on Expanding Access, Label Extension, Product Profile Robust clinical program supported by new $43.1 million CEPI grant1 Post-Marketing Effectiveness2 (Phase 4) To confirm effectiveness following licensure based on an immunological surrogate of protection and to optimize description
Slide 13: World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate
World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate S4V2
Slide 14: S4V2: Opportunity to Develop First-in-Class Vaccine for a Life-Threatening Disease
S4V2: Opportunity to Develop First-in-Class Vaccine for a Life-Threatening Disease Tetravalent bioconjugate vaccine with potential to cover up to ~85% of shigellosis infections 1 Vaccine Highlights Market Opportunity Upcoming Milestones • World’s most clinically advanced tetravalent • Global market
Slide 15: Novel Zika Virus Vaccine Candidate
Novel Zika Virus Vaccine Candidate VLA1601
Slide 16: VLA1601: Optimized Vaccine Candidate Against Zika Virus
VLA1601: Optimized Vaccine Candidate Against Zika Virus Phase 1 results expected this year Vaccine Highlights Market Opportunity Upcoming Milestones • Novel adjuvanted inactivated whole- • Flaviviral disease transmitted by • Execute Phase 1 clinical trial with virus vaccine Aedes mosquitoes2 enhance
Slide 17: Agenda
Agenda Introduction Business Update Financial Report H1 2025 Financial Outlook Growth Drivers Q&A Valneva – H1 2025 Analyst Presentation 17
Slide 18: H1 2025 Financials: Product Sales of €91 million
H1 2025 Financials: Product Sales of €91 million Reflects supply of IXCHIQ®/DUKORAL® to areas in need; recovery of supply shortages for IXIARO® and third-party products €m (audited) H1 H1 % 2025 2024 Change IXIARO®/JESPECT® 54.7 41.9 30.6% DUKORAL®* 17.4 14.9 16.4% IXCHIQ®** 7.5 1.0 688% Third party
Slide 19: H1 2025 Financials: Income Statement
H1 2025 Financials: Income Statement €m (unaudited) H1 2025 H1 2024 Product sales 91.0 68.3 Other Revenues 6.5 2.5 Revenues 97.6 70.8 Cost of goods and services (47.2) (45.6) Research and development expenses (32.4) (29.7) Marketing and distribution expenses (20.3) (23.2) General and administrative
Slide 20: Agenda
Agenda Introduction Business Update Financial Report H1 2025 Financial Outlook Growth Drivers Q&A Valneva – H1 2025 Analyst Presentation 20
Slide 21: Valneva Remains Solidly Funded with Strong Financial Outlook
Valneva Remains Solidly Funded with Strong Financial Outlook 2025 Guidance Financial Outlook ▪ Product Sales: €170 - €180 million1; Commercial ▪ Continued revenue growth and cash flows from business expected to be cash-flow positive commercialized vaccines ▪ Total Revenues: €180 - €190 million ▪ Foc
Slide 22: Agenda
Agenda Introduction Business Update Financial Report H1 2025 Financial Outlook Growth Drivers Q&A Valneva – H1 2025 Analyst Presentation 22
Slide 23: Valneva Outlook: Growth Drivers for 2025 and Beyond
Valneva Outlook: Growth Drivers for 2025 and Beyond VLA15 success case • Potential for sustained profitability upon potential approval and commercialization*, driven by substantial milestones and royalties starting in 2027 Growing commercial revenues • Near term: continued growth trajectory of IXIAR
Slide 24: Agenda
Agenda Introduction Business Update Financial Report H1 2025 Financial Outlook Growth Drivers Q&A Valneva – H1 2025 Analyst Presentation 24
Slide 25: Thank you
Thank you Merci Danke Tack valneva